Physician profile
Melissa DO
NPI 1144849787
$10,202.39
in general payments reported to CMS, 2019-2025
58 companies · $1,671 in 2025
The $1,671 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $864 · 2022: $600 · 2023: $2,162 · 2024: $4,906 · 2025: $1,671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,825 · Travel and Lodging: $897 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,824.97 |
| Travel and Lodging | $896.64 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,578.27 | 2023-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $942.50 | 2023-2025 | Briviact, Fintepla, Rystiggo |
| Abbvie INC. | $691.69 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $519.73 | 2022-2025 | Ponvory |
| Eisai INC. | $436.72 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $365.57 | 2023-2025 | Nuplazid, Daybue |
| Pfizer INC. | $359.30 | 2023-2025 | |
| Lundbeck LLC | $348.97 | 2021-2025 | Vyepti, Rexulti |
| Sk Life Science, INC. | $309.69 | 2023-2025 | |
| Neurelis, INC. | $281.66 | 2023-2024 | Valtoco |
| Lilly USA, LLC | $275.48 | 2023-2025 | Amyvid, Kisunla, Emgality |
| Takeda Pharmaceuticals U.S.A., INC. | $253.37 | 2021-2025 | Trintellix, Hyqvia |
| Jazz Pharmaceuticals INC. | $246.26 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $241.79 | 2023-2025 | |
| Merz Pharmaceuticals, LLC | $237.48 | 2023-2025 | Xeomin |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $195.19 | 2023-2024 | Aptiom |
| Neurocrine Biosciences, INC. | $189.45 | 2021-2025 | Ingrezza, Ongentys |
| Tg Therapeutics, INC. | $186.80 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $185.48 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $183.32 | 2022-2025 | Austedo Xr, Austedo Xr |
| Biogen, INC. | $145.19 | 2023-2025 | Skyclarys, Skyclarys, Tysabri |
| Otsuka America Pharmaceutical, INC. | $145.03 | 2022-2023 | Rexulti, Nuedexta |
| Supernus Pharmaceuticals, INC. | $131.72 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $125.28 | 2024-2025 | |
| Immedica Pharma US, INC. | $125.28 | 2024-2025 | Ztalmy |
| Grifols USA, LLC | $115.77 | 2023-2025 | Gamunex-C |
| Almatica Pharma LLC | $115.16 | 2022-2023 | Sertraline Hcl, Loreev Xr |
| Corium, LLC | $104.73 | 2022-2023 | Azstarys, Adlarity |
| Argenx US, INC. | $101.94 | 2025 | Vyvgart Hytrulo |
| Octapharma USA, INC. | $94.55 | 2024-2025 | Panzyga |
| Alexion Pharmaceuticals, INC. | $87.26 | 2024 | Ultomiris, Soliris |
| Sunovion Pharmaceuticals INC. | $80.47 | 2022 | |
| Alnylam Pharmaceuticals INC. | $60.99 | 2023-2025 | Onpattro |
| Merck Sharp & Dohme LLC | $59.03 | 2021-2023 | Belsomra |
| Ipsen Biopharmaceuticals, INC | $53.99 | 2024 | Dysport |
| Acorda Therapeutics, INC | $49.88 | 2023-2024 | Inbrija |
| Aucta Pharmaceuticals, INC. | $47.84 | 2024 | Motpoly Xr |
| Amneal Pharmaceuticals LLC | $40.98 | 2024 | Rytary |
| Ani Pharmaceuticals, INC. | $40.62 | 2024 | Purified Cortrophin Gel |
| Alkermes, INC. | $40.44 | 2022-2023 | Lybalvi |
| Neos Therapeutics, LP | $38.73 | 2022 | |
| Adlon Therapeutics L.P. | $38.29 | 2021 | |
| Janssen Pharmaceuticals, INC | $35.76 | 2023 | Spravato |
| Ns Pharma, INC. | $35.34 | 2023-2025 | Viltepso |
| Scilex Pharmaceuticals INC. | $35.16 | 2024 | |
| Axsome Therapeutics, INC. | $26.19 | 2023 | Sunosi |
| Csl Behring | $21.58 | 2023 | Hizentra |
| Owp Pharmaceuticals, INC. | $21.31 | 2021 | |
| Azurity Pharmaceuticals, INC. | $20.37 | 2024 | Horizant |
| Emd Serono, INC. | $18.44 | 2023 | Mavenclad |
| Kedrion Biopharma, INC. | $18.11 | 2024 | Kedrab, Gammaked, Koate |
| Medtronic, INC. | $17.82 | 2022 | |
| Alfasigma USA, INC. | $17.37 | 2021 | |
| Ge Healthcare | $14.24 | 2024 | |
| Idorsia Pharmaceuticals US INC | $14.21 | 2023 | Quviviq |
| Bausch Health US, LLC | $14.01 | 2022 | |
| Avanir Pharmaceuticals, INC. | $11.96 | 2021 | |
| Cycle Pharmaceuticals INC | $8.63 | 2024 | Tascenso Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.